Stress and hormones released in response to stress influence the effects of nicotine and the severity of nicotine withdrawal. Here, we systematically examine the contribution of a stress response gene, FKBP5, to the acute and chronic behavioral effects of nicotine in smokers. Subjects were European-and African-American (EA and AA) heavy smokers who participated in an intravenous (IV) nicotine administration study (total n = 169). FKBP5 rs3800373 genotype was analyzed for association to several outcomes, including nicotine withdrawal and the acute subjective, heart rate (HR), blood pressure and plasma cortisol responses to IV nicotine. Nicotine withdrawal was also examined in relation to rs3800373 allele frequencies in an independent cohort of EA and AA current smokers (n = 3821). For a subset of laboratory subjects FKBP5 mRNA (n = 48) expression was explored for an association to the same outcomes. The rs3800373 minor allele was associated with less severe nicotine withdrawal in laboratory subjects and the independent cohort of smokers. The rs3800373 minor allele was also associated with lower subjective ratings of negative drug effects in response to IV nicotine. Low FKBP5 mRNA expression was associated lower cortisol levels, lower subjective ratings of negative drug effects and a blunted HR response to nicotine. Stress hormone regulation via FKBP5 warrants further investigation as a potential contributor to the effects of nicotine withdrawal, which occurs commonly, and has an important role in the maintenance of smoking behavior and relapse following a quit attempt.
INTRODUCTION
Exposure and the differential response to stressful stimuli affect the development and maintenance of dependence on a number of drugs, including nicotine. 1 The important role of stress with respect to risk of nicotine dependence (ND) is evident when one considers the high prevalence of ND in stress-related disorders such as posttraumatic stress disorder (PTSD). Individuals with PTSD are about twice as likely to have ND as those without PTSD. 2 Further, smokers with PTSD smoke more cigarettes per day, report experiencing more severe withdrawal symptoms and have lower quit rates than smokers without PTSD. 3, 4 Although, the underlying mechanisms that link stress-related disorders to ND have not been fully elucidated, disturbances in stress response and hypothalamicpituitary-adrenal (HPA) axis activation are the focus of intense research. HPA axis abnormalities are a hallmark of stress-related disorders such as PTSD, 5 and subjects with PTSD responded differently to stressful stimuli compared with subjects unaffected by PTSD. 6 There are consistent findings across basic neurobiological and genetic studies that the gene encoding FK506 binding protein 5 (FKBP5) is among those that modulates the stress response and HPA axis activity in humans. FKBP5 has been linked to stress hormone dysregulation, 7-9 risk of PTSD, anxiety disorders and depressive disorder, [10] [11] [12] [13] [14] and recently, alcohol withdrawal. 15 FKBP5 functions in a feedback loop that regulates HPA axis activity. FKBP5 expression is induced by glucocorticoids 16 and the encoded protein, FK506 binding protein 51, represses glucocorticoid receptor signaling. 17 The HPA axis and the nicotinic cholinergic system are closely linked. However, the function of this critical regulatory gene in the context of smoking-related behaviors and the effects of nicotine has not been thoroughly investigated. Nicotine activates the HPA axis in a dose-dependent fashion, resulting in the release of adrenocorticotropic hormone and cortisol. 18, 19 Glucocorticoids have been shown to inhibit or desensitize the nicotinic acetylcholine receptors 20, 21 and may enhance nicotine self-administration in rats possibly by increasing the dose needed to produce a particular level of reinforcement. 22 Stress hormones also influence the severity of nicotine withdrawal in rats 23 and potentially, relapse to smoking in humans. 24, 25 Thus, FKBP5, a stress-response gene, may function in pathways that modulate sensitivity to nicotine and the severity of nicotine withdrawal. To our knowledge, no previous studies have examined the modulation of nicotine responses and withdrawal severity by FKBP5.
The goal of this study was to examine systematically the contribution of FKBP5 to the acute and chronic behavioral effects of nicotine in smokers, starting with a laboratory paradigm. We included European-American (EA) and African-American (AA) heavy smokers. The behavioral outcomes studied were nicotine withdrawal severity and the acute subjective, heart rate, blood pressure and plasma cortisol responses to intravenous (IV) nicotine. In addition, the effect of FKBP5 variation on nicotine withdrawal severity was examined separately in a large cohort of EA and AA current smokers who participated in genetic studies of substance dependence.
MATERIALS AND METHODS

Nicotine laboratory study: subjects, procedure and assessments
Non-treatment-seeking smokers (n = 169) were recruited from the New Haven, Connecticut area for a laboratory study examining the factors that moderate nicotine withdrawal and reward. Subjects from this population have been included in previous studies, including genetic studies. 26, 27 All participants smoked at least 10 cigarettes/day and were otherwise medically healthy. Subjects were evaluated with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fourth Edition (DSM-IV) 28 and subjects who were dependent on alcohol or drugs (other than nicotine) or were affected with any major psychiatric disorder were excluded from the study. A urine drug screen verified lack of drug use other than nicotine. Demographic information and smoking-related characteristics for the laboratory subjects are shown in Supplementary Information ( Supplementary Table S1 ).
The study procedure has been described in detail elsewhere. 26, 27 Briefly, experimental sessions were conducted in the morning (0800) after an overnight abstinence from smoking that was confirmed biochemically. All laboratory subjects had expired carbon monoxide levels o10 p.p.m. and plasma nicotine levels o4 ng ml − 1 , indicating abstinence from smoking. After IV lines were established, at baseline, subjects completed the Minnesota Nicotine Withdrawal Scale (MNWS), 29 the Positive and Negative Affect Schedule (PANAS) 30 and the Brief Questionnaire of Smoking Urges (BQSU). 31 They then were administered an IV dose of saline, followed by two doses of IV nicotine per 70 kg of body weight: a moderate dose (0.5 mg) and a high dose (1 mg) in uniform order, separated by 30 min. During the experimental session, blood pressure and heart rate were monitored and the effects of nicotine were assessed with the Drug Effects Questionnaire (DEQ). Approximately 20 min after the final dose of nicotine, subjects repeated the MNWS, PANAS and BQSU assessments. Institutional review boards at Yale University and VA Connecticut Healthcare System (West Haven, CT) approved the study, written consent was provided before participating in the study, and subjects were paid for their participation.
DSM-IV-based withdrawal symptoms in current smokers
Subjects were recruited at multiple Eastern-US sites for genetic studies of drug and alcohol dependence, including genome-wide association studies of alcohol, 32 cocaine, 33 opioid 34 and ND. 35 The institutional review board at each participating site approved the studies and all subjects provided written informed consent to participate. The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism issued Certificates of Confidentiality to protect study participants. The sample's demographic details, smoking-related information and major psychiatric diagnoses are shown in Supplementary Information (Supplementary Table S2 ). The subjects were interviewed using the polydiagnostic Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA) to obtain DSM-IV diagnoses for all major psychiatric disorders and the additional variables used in the analysis. 36 Subjects included in this analysis were current cigarette smokers, that is, they had smoked within the last week. A smoking withdrawal symptom score was calculated by summing the reports of DSM-IV smoking withdrawal symptoms. Specifically, subjects were asked about problems that they might have had when they stopped smoking or smoked less tobacco than usual. They answered 'yes' or 'no' to each of nine questions: (i) Were you irritable, angry or frustrated? (ii) Were you nervous or anxious? (iii) Were you restless? (iv) Did you have trouble concentrating? (v) Did your heart slow down? (vi) Did you feel down or depressed? (vii) Did you have such a strong desire for cigarettes that you couldn't think of anything else? (viii) Did your appetite increase or did you gain weight? (ix) Did you have trouble sleeping? In a separate stage of this assessment, subjects were asked whether the symptoms i-vii lasted for at least 24 h. For each assessment, only subjects that reported at least one withdrawal symptom were included in the analysis.
Genotyping and genetic analysis
Laboratory participants were genotyped for rs3800373 with a 2 μl TaqMan allelic discrimination assay (Applied Biosystems, Foster City, CA, USA). This single-nucleotide polymorphism (SNP) tags a previously studied common FKBP5 haplotype. [11] [12] [13] [14] 37 Laboratory subjects were assigned to EA or AA subject groups on the basis of a previously described genetic marker method 26, 38 or on the basis of the self-report. Rs3800373 was directly genotyped for subjects with DSM-IV-based withdrawal symptoms by either the HumanOmni1-Quad v1.0 or the Infinium HumanCore Exome BeadChip (Illumina, San Diego, CA, USA). One subject was retained from each pair determined to be related (identity-by-descent 40.25), and subjects with sex-mismatches were excluded. The overall genotype-missing rate was o2%. The array-genotyped subjects were clustered as EA or AA on the basis of the first two principal components, and subjects with clustering that was discordant from their self-reported race were excluded.
Data analysis
Laboratory data were analyzed using mixed models with the following independent variables: age, sex, race (EA or AA), FKBP5 rs3800373 (coded as minor allele carrier versus TT to increase power), ordered experimental dose (saline, 0.5 mg nicotine and 1 mg nicotine per 70 kg body weight) and the interaction of experimental dose with FKBP5 genotype (as fixed effects) and subject (as a random effect). Rs3800373 distributions are shown in Supplementary Table S1 and S2. On the basis of prior work suggesting that the DEQ items may not represent independent constructs, 39 we factor analyzed the DEQ prior to conducting statistical analyses and found evidence for the following three domains: (i) 'stimulatory' effects comprising 'feel stimulated', 'feel effects' and 'feel high'; (ii) 'feel good' effects comprising 'like', 'feel good' and 'want more'; and (iii) 'negative' effects comprising 'feel anxious', 'feel down' and 'feel bad'. Each response was rated on a visual 100 mm scale that was then converted to a rating from 1 to 10. Blood cortisol levels were collected at five time points described in Figure 3 . Log-transformed cortisol levels were analyzed in mixed models that included the interaction of FKBP5 genotype with time point rather than experimental dose. MNWS, PANAS and BQSU data were analyzed at the pre-and post-nicotine conditions separately with age, sex and race as covariates. DSM-IV nicotine withdrawal symptoms were summed, logtransformed and analyzed in regression models that used age, sex, anxiety or depression diagnosis (coded dichotomously), the first three PCs (determined for the EA and AA populations separately), and rs3800373 (coded as minor allele carrier versus TT) as predictors. The results for EAs and AAs were combined by meta-analysis. Analyses and quality control procedures were performed using PLINK 40 and JMP Pro 10.0.
RNA expression analysis
For a subset of laboratory subjects (N = 48) whole blood was collected into PAXgene Blood RNA tubes (PreAnalytiX, Hombrechtikon, Switzerland) for RNA analysis. All experimental sessions began at 0800 and blood for RNA analysis was collected immediately prior to saline infusion for all subjects. RNA was extracted with the PaxGene Blood miRNA Kit (Qiagen, Hilden, Germany). The RNA quality was checked with an Agilent Bioanalyzer and the average RNA Integrity Number was 8.7 (range = 6.2-9.9). An additional purification step was performed with the RNeasy MinElute Cleanup kit (Qiagen) to reduce salt concentrations. RNA was prepared for hybridization to HumanHT-12 v4 arrays at the Yale Center for Genome Analysis (YCGA) using the Illumina TotalPrep RNA Amplification kit (Life Technologies/ Ambion, Foster City, CA). After hybridization, the arrays were scanned with a Bead Array Reader (Illumina, San Diego, CA, USA). Gene-level expression values were cubic-spline normalized using BeadStudio software (Illumina, San Diego, CA, USA). All subjects had FKBP5 expression values above a threshold detection level of Po0.00001. RNA expression was analyzed using mixed models as described above for genotype. To validate the array-based FKBP5 expression values we used RT-PCR to confirm the association with cortisol levels. RNA from 24 subjects (from 4 different arrays) was reverse transcribed using the ABI High Capacity cDNA Archive Kit (Applied Biosystems) according to the manufacturer's specifications. One-fortieth of each cDNA reaction was amplified in triplicate in a 10 μl PCR reaction containing 500 nM forward and 500 nM reverse primer, 0.1 × Sybr Green I (Molecular Probes, Eugene, OR, USA), and 1 × TaqMan Genotyping Master Mix (Applied Biosystems) using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). The expression of a housekeeping gene, HPRT, was used to normalize expression values between subjects. Primer sequences were, HPRT Fwd 5ʹ-TGAGGAT TTGGAAAGGGTGT-3ʹ, HPRT Rev 5ʹ-CCTCCCATCTCCTTCATCAC-3ʹ, FKBP5 Fwd 5ʹ-AAGTTTGCAGAGCAGGATGC-3ʹ, FKBP5 Rev 5ʹ-GGCCCTCAGGTTTCTCT TCT-3ʹ. The relative level of gene expression was determined with the ΔΔCt method using the mean value of two experiments. Consistent with array-based results, the mean-cycle threshold was associated with cortisol levels at time point 1 (Figure 1 ) in a regression model adjusted for age, sex and race (P o0.05, Supplementary Figure S1 ).
RESULTS
FKBP5 variation and nicotine withdrawal severity
Smokers with the rs3800373*C allele, compared with those homozygous for the A allele, reported lower MNWS scores at baseline (main effect for group: F (1,164) = 7.37; P o 0.010), but not after nicotine (Figure 1a ). FKBP5 mRNA was not associated with MNWS, nor was FKBP5 genotype or mRNA associated with QSU or PANAS scores.
To extend our observation on the nicotine-related behavioral effects of FKBP5 variation, we examined the association of rs3800373 to nicotine withdrawal symptoms in a population of current EA and AA smokers (EA and AA; total n = 3821) that were recruited for genetic studies of substance dependence. The demographic characteristics and major psychiatric comorbidities are shown in Supplementary Table S2 (Supplementary Information). We examined subjects' reports of any DSM-IV nicotine withdrawal symptom and those lasting for 24 h. Subjects with at least one rs3800373*C allele reported fewer nicotine withdrawal symptoms than those homozygous for rs3800373*A (Figure 1b ; main effect for group: P meta o 0.05) and fewer nicotine withdrawal symptoms that lasted for 24 h (main effect for group: P meta o 0.005). Mean withdrawal counts for the EA and AA genotype groups from each array are shown in Supplementary  Table S3 (Supplementary Information). In this analysis, comorbid anxiety or depression was used as a covariate in the regression models to control for the effects of anxiety and depression on the severity of withdrawal symptoms. Figure 2a ). There was a modest genotype-by-dose interactive effect on reports of 'feel good' effects (group-by-time interaction; F (1, 192) = 4.0; P o0.05), with no significant group differences for the saline or nicotine doses (Supplementary Figure S2 ).
Smokers with low FKBP5 mRNA levels reported lower levels of 'negative' effects in response to nicotine than those with high FKBP5 mRNA (group-by-dose interaction: F (2,762) = 5.62; P o 0.005; Figure 2a ). The association of FKBP5 mRNA-by-dose to 'negative' effects was independent of rs3800373 genotype. In a regression model that included genotype and genotype-by-FKBP5 mRNA, there was no significant main (or interactive) effect of genotype, whereas the FKBP5 mRNA-by-dose term remained significant. Likewise, including baseline cortisol levels, array number (1-4), cigarette pack-years, and RNA Integrity Number as covariates in the model had little effect on the P-value for the FKBP5 mRNA-bydose term.
Smokers with low FKBP5 mRNA had a blunted HR response to nicotine (group-by-dose interaction; F (2,887) = 7.8; P o 0.0005; Figure 2b ). The HR effect was most evident in the minute following nicotine administration. There was also a modest mRNA-by-dose effect on systolic BP (group-by-dose interaction; F (2,908) = 4.7; P o 0.01; Supplementary Figure S3 ). The HR effects were independent of genotype, baseline cortisol levels, array number, cigarette pack-years and RNA Integrity Number, which were entered into the models in post hoc analyses. FKBP5 genotype was not associated to HR or BP outcomes (Supplementary Figure S3 ).
FKBP5 variation and cortisol regulation in smokers
Smokers with low FKBP5 mRNA expression had lower cortisol levels than those with high FKBP5 expression (main effect for group: F (1,118) = 9.46; P o0.005 and group-by-time interaction: F (1,184) = 2.9; Po 0.05). Consistent with these findings, FKBP5 mRNA expression was associated with cortisol at baseline before the initiation of nicotine administration (r 2 = 0.20, P = 0.001), but not at the end of the study (Figure 3 ). The cortisol effects were independent of genotype, array number, cigarette pack-years and RNA Integrity Number, which were entered into the models in post hoc analyses. FKBP5 genotype was not associated with cortisol levels. The RNA-cortisol relationship was confirmed by RT-PCR (Supplementary Figure S1 ).
DISCUSSION
We found that variation in FKBP5 was associated with nicotine withdrawal severity, the acute behavioral and physiological effects of nicotine, and cortisol regulation during nicotine withdrawal. FKBP5 genotype was associated with withdrawal severity in the subjects both in a laboratory study and in an independent larger cohort of current EA and AA smokers. FKBP5 genotype and RNA expression were associated with differences in the acute negative subjective effects of IV nicotine, whereas FKBP5 RNA expression was associated with HR response to IV nicotine. FKBP5 mRNA expression was positively correlated with cortisol levels during nicotine withdrawal, but not after IV nicotine administration. Our investigation of effects at the RNA level provided convergent support for some of the genotype effects. For example, FKBP5 mRNA expression and genotype were both associated with the 'negative' drug effects domain of the DEQ. Combined, these findings reaffirm the importance of HPA axis regulation via FKBP5 and show that FKBP5 variation at the DNA and RNA levels contributes to some inter-individual differences in nicotine-related behavior.
The association of FKBP5 genotype with nicotine withdrawal severity in laboratory study participants and the large cohort of current smokers may have clinical relevance, as withdrawal severity is a strong predictor of relapse to smoking. 41 Our findings regarding FKBP5 and nicotine withdrawal are consistent with a recent report of an association of FKBP5 to alcohol withdrawal in humans and mice. 15 In the Huang et al. 15 study, subjects with the FKBP5 rs3800373 minor allele reported less withdrawal. Together, these findings suggest that some effects of FKBP5 generalize to multiple addictive substances. Indeed, withdrawal symptoms that emerge during abstinence contribute to the maintenance of addiction to nicotine, 41 alcohol 42 and other drugs. 43 These negative effects, as opposed to the positive reinforcing effects, that develop from drug use warrant attention, as they might be mechanistically distinct but independently important for the development of addiction. The pronounced effect of PTSD co-morbidity on nicotine withdrawal suggests that stress-reactivity pathways are central to the negative effects that occur during nicotine withdrawal. Stress hormones modulate the activity of neurotransmitter systems in brain regions that are essential for the development and maintenance of addiction to nicotine and other substances. For example, stress hormones alter dopaminergic activity in the ventral tegmentum 44 and the nucleus accumbens. 45 The activity of stress hormones in the nucleus accumbens may contribute to the withdrawal effects of nicotine. Marcinkiewcz et al. 46 found that blocking CRF signaling specifically in the nucleus accumbens reduced nicotine withdrawal in rats. We observed an association of FKBP5 genotype and mRNA expression to subjective reports of 'negative' drug effects during the human laboratory study. Genotype group differences were greatest during the saline condition and absent at the highnicotine condition. During the saline condition, the minor allele carriers reported less 'negative' drug effects. In contrast, mRNA expression differences were absent during the saline condition and greatest during the high-nicotine condition. Subjects with low FKBP5 expression reported less 'negative' drug effects in response to nicotine relative to subjects with high FKBP5 expression. We also found that subjects with low FKBP5 mRNA expression had a blunted HR response to nicotine compared with subjects with high FKBP5 mRNA expression, but genotype was not associated with HR response. Stress hormones reduce the sensitivity of nicotinic receptors to nicotine, 20, 21, 47 and they moderate the acute behavioral and HR response to nicotine in animal models. 48, 49 Our findings regarding FKBP5 variation and the acute subjective and HR response to nicotine may reflect FKBP5-dependent stress hormone modulation of nicotinic receptor sensitivity in humans.
We observed a positive correlation between cortisol levels and FKBP5 mRNA, but not genotype, which is consistent with previous reports. 12 The correlation with cortisol levels was strongest when subjects were in nicotine withdrawal and disappeared after IV nicotine administration. Our findings are consistent with previous studies demonstrating the regulatory influence of FKBP5 on glucocorticoid receptors. 17, 50 The acute and chronic effects of nicotine exposure on stress hormone levels are relevant to many clinical features of ND. For example, work by Cohen et al. 51 suggests that cortisol level correlates with nicotine withdrawal severity after an acute-withdrawal period, whereas others have reported correlations between cortisol and risk of relapse to smoking. 24, 25 Additional investigations on the relationship of FKBP5 variation to cortisol levels and the behavioral correlates of FKBP5 mRNA levels in smokers are warranted.
These findings suggest that FKBP5, which has a central function in stress hormone regulation, could be a useful marker for susceptibility to severe nicotine withdrawal and could help to identify individuals at the greatest risk for relapse to smoking following a quit attempt. FKBP5 may also be useful in understanding the link between stress-related disorders, such as PTSD, and the severe nicotine withdrawal that often accompanies it. Treatment of these co-occurring disorders is especially difficult and when they are comorbid, negative health effects may be amplified. 3, 4 Risk for ND and PTSD is influenced by genetic variation, with a significant proportion of this risk being common to both disorders. 52 FKBP5 could be a common factor involved in facets of each trait. Also, given its role in modulating the withdrawal severity, variation in FKBP5 has implications for smoking cessation. This possibility is supported by a study showing that glucocorticoid agonists may reduce cigarette craving and satisfaction in smokers. 53 The subjects in the gene expression study (n = 48) were also transcriptome analyzed after the final injection of nicotine (data not shown). Relative to the pre-saline condition, we observed an~25% reduction in FKBP5 mRNA after the final nicotine injection. This effect was significant based on a transcriptome-wide test correction (Bonferroni-corrected significance threshold P o 9.8 × 10 − 6 ), but given the uniform order of administration, saline followed by nicotine, we cannot confidently attribute the gene expression change to the effects of nicotine. This effect, although potentially important, requires additional study.
Our observations on the effects of FKBP5 variation at the DNA and RNA levels are consistent in many respects; however, our study has limitations. To reduce the likelihood that our findings were the result of type-1 error we conducted replication studies in independent samples and additional studies on mRNA expression that provided convergent support, but type-1 error cannot be excluded, and replication and extension of these findings will be important. We limited our genotype association analysis to a previously studied SNP to limit the number of statistical tests conducted to preserve power, and to allow for direct comparisons with the two arrays used in our follow-up study on withdrawal effects. On the basis of prior literature we anticipated that rs3800373 would be highly correlation with rs1360780, an FKBP5 SNP with a putative regulatory function in glucocorticoid receptor binding to DNA. 10 Rs3800373, rs1360780 and additional SNPs that form a common FKBP5 haplotype, have been reported to be associated to the presence of a number of different psychiatric traits in EAs and AAs. [11] [12] [13] [14] 37 We confirmed our expectations regarding linkage disequilibrium with a post hoc examination of rs1360780 in the laboratory sample; as expected the linkage disequilibrium (determined with Haploview 54 ) for rs3800373 and rs1360780 was high (r 2 40.9 and D'40.95). Given the LD structure of the gene, a much larger sample will be required to clearly distinguish the independent effects of FKBP5 SNPs (and other variants). The FKBP5 mRNA findings were independent of genotype in our statistical models, but the power to detect interactive or moderating effects of genotype may have been limited by the modest sample size. Alternatively, cell specificity could favor the detection of FKBP5 SNP effects on gene expression in cells from tissues, such as brain, that are more relevant to the behavioral effects of stress, nicotine and nicotine withdrawal. It is interesting that FKBP5 genotype and mRNA are both associated with the 'negative' effects domain of the DEQ. Each effect is interactive with nicotine dose, but, as noted above, the effect profiles differ. This may indicate that FKBP5 mRNA expression in blood cells captures some nicotine-related effects not captured by FKBP5 genotype. Unraveling the relationship between these dynamic effects will require additional work.
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